Short-course treatment in

neurobrucellosis: A study in Iran by Abbasi, Farhad et al.
 101Neurology India | Jan-Feb 2011 | Vol 59 | Issue 1
Address for correspondence:
Dr. Farhad Abbasi,  
Fateme-alzahra Hospital, Siraf St, 
Bushehr, Iran. 
E-mail: f_abbasi55@yahoo.com 
Received : 04-09-2010
Review completed : 26-09-2010
Accepted : 13-10-2010
Short-course treatment in 
neurobrucellosis: A study in Iran
Kamyar Asadipooya, Amirreza Dehghanian1, Gholam Hossein Ranjbar Omrani1, Farhad Abbasi2
Persian Gulf Institute, Bushehr University of Medical Sciences, Bushehr, 1Namazi Hospital,  University of Medical Sciences, Shiraz,  
2Bushehr University of Medical Sciences, Bushehr, Iran
Abstract
Neurobrucellosis is a rare neurological complication of brucellosis. This report describes 
19 patients of neurobrucellosis and they accounted for 8% of all cases of brucellosis 
admitted to Shiraz University Hospitals over a period of eight years. Headache, fever, 
fatigue, drowsiness and neck stiffness were the common clinical features. Cerebrospinal 
fluid (CSF) showed pleocytosis in 100%, elevated protein levels in 89% and low glucose 
level in 47% of the patients. All the patients improved with specific antibiotic treatment. 
Of the 19 patients, 10 (52.5%) patients received treatment for 8 to 28 weeks. Duration 
of antibiotic treatment was: 8-14 weeks in 8 (42%) patients; 24-28 weeks in 2 (10.5%) 
patients; 6 months in 7 (37%) patients; 12 months in 1 (5.3%) patient; and 18 months 
in 1 (5.3%) patient. Clinicians in endemic areas should consider the likelihood of 
neurobrucellosis in patients with unexplained neurological and psychiatric symptoms.
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Introduction
Central nervous system (CNS) involvement is a 
serious complication of brucellosis[1] Neurobrucellosis 
occurs in 5–10% of cases of brucellosis.[2] Neurological 
complications can be categorized into two major 
groups: 1) those related to the acute-febrile phase of 
the illness, toxic-febrile neurobrucellosis and 2) those 
related to primary affection of central and peripheral 
nervous system by the brucella infection.[2] CNS 
involvement is commonly acute and results mainly in 
meningoencephalitis, while peripherial nervous system 
(PNS) involvement may be either acute or chronic.[3] In 
this article, we report  the clinical characteristics and 
treatment strategies of 19 patients with neurobrucellosis.
Material and Methods
This is a retrospective study of patients with 
neurobrucellosis admitted to two tertiary care hospitals 
in Shiraz, Iran over a period of eight years. Diagnostic 
criteria for neurobrucellosis were: 1) clinical features 
compatible with a known neurobrucellosis syndrome; 
2) typical cerebrospinal fluid (CSF) (elevated protein 
concentration or pleocytosis) findings; 3) positive blood 
or CSF serology for brucellosis (e.g., agglutination test 
titers of >1:160 in blood or any positive titer in CSF); 4) 
clinical improvement with a course of antibiotic therapy; 
and 5) clinical syndrome otherwise not explainable by an 
alternative diagnosis. Case records were reviewed and 
the data collected included clinical features, laboratory 
data, neuroimaging findings, treatment details, and 
outcome. Serum anti-brucella immunoglobulin G (IgG) 
and immunoglobulin M (IgM) 	antibody were	checked for 
patients who had negative Coomb’s Wright agglutination 
tests results by enzyme-linked immunosorbant assay 
(ELISA) method. Antibiotic treatment included: 
doxycycline, rifampin, trimethoprim-sulfamethoxazole, 
streptomycin, gentamicin and ceftriaxone. Treatment 
was discontinued after clinical assessment by the 
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physicians when they were certain that the infection was 
controlled. All patients were followed for two years to 
find any signs and symptoms of relapse.
Results
Of the 235 patients with brucellosis admitted during 
the study period, 19 (8%) patients had neurobrucellosis. 
Mean age was 38.1 years (range 18 – 70 years) and 
there were 14 (74%) were males. The mean duration of 
symptoms before admission was 8 weeks (range 1 week 
– 4 months). The most common clinical features were: 
headache (79%), fever (84%), neck rigidity (42%), fatigue 
(37%), altered mental status (31%), speech disturbances 
(21%), nausea and vomiting (15%). Other less common 
clinical features were hearing loss, paraplegia, cerebellar 
ataxia, diplopia, photophobia, blurred vision, abnormal 
behavior, hypoesthesia, low back pain and right-side 
weakness. Ten (58%) patients had focal neurological 
deficits. 
CSF analysis showed elevated protein (> 45 mg/dl) in 
17 (89%) patients. low glucose (< 40 mg/dl and/or CSF/
serum glucose ratio of < 0.4) in nine (47%) patients. CSF 
WBC count was between 6 cells/dl and 3600 cells/dl 
with mean count 403 cells/dl. Fifteen (79%) patients had 
lymphocyte predominance and four (21%) patients had 
polymorphonuclear (PMN) predominance. CSF cultures 
and Gram-stains were negative in all patients. Of the 
six sera tested for anti-brucella antibody, 3 (50%) were 
positive.  Anti-brucella antibodies in the CSF by either 
ELISA or Coomb’s Wright agglutination tests were tested 
in 9 patients that was positive in 6 (67%) patients.
Three patients had electrodiagnostic evidence of 
peripheral neuropathy. Brain computed tomography 
(CT) scan was done in 12 patients; only one scan showed 
infarct in the anterior limb of left internal capsule. This 
patient had right hemiparesis. Brain magnetic resonance 
imaging (MRI) was performed in eight patients with 
normal brain CT scan. Scans in two patients showed 
abnormalities;   (1) a-23-year old male with  one history 
of hearing loss and three month history of severe 
headache showed mild hydrocephalus with right 
temporal atrophy; and (2) a-27-year old male  with one 
week history of fever, headache, inappropriate speech, 
abnormal behavior, and seizures showed putamenal 
infarctions. 
Eight (42%) patients who presented with fever, headache 
and/or drowsiness and no focal deficits, received 
8-14 weeks’ antibiotic therapy (doxycycline, rifampin 
and trimethoprim-sulfamethoxazole or streptomycin 
or ceftriaxone). Two patients with hearing loss had 
received 24 and 28 weeks of antibiotics respectively 
(doxycycline, rifampin, trimethoprim-sulfamethoxazole 
and ceftriaxone for the first month). Both the patients 
improved significantly in their hearing as shown in the 
followup audiometric studies. One patient with lower 
extremity weakness and peripheral neuropathy received 
1.5 year antibiotic therapy 	(doxycycline, rifampin	 and 
trimethoprim-sulfamethoxazole). One patient with 
headache and photophobia with normal brain CT 
scan and brain MRI received one month doxycycline, 
rifampin and streptomycin. Treatment was continued 
by doxycycline and rifampin for 11 months. Seven 
patients (37%) had received six months’ antibiotic 
therapy with doxycycline, rifampin and trimethoprim-
sulfamethoxazole or ciprofloxacin or gentamicin 
(ceftriaxone for the first month). All the patients 
improved without any sequela and none had relapse 
during the two years’ follow-up. Follow-up was done by 
visiting the patients and also by telephone. There were no 
side-effects related to long-term aminoglycoside therapy. 
Mild transient elevation of liver enzyme occurred in 
some patients with rifampin. One patient died in the 
second year because of a cardiac event at the age of 70.
Discussion
Brucellosis is a multisystem disease with a broad spectrum 
of clinical manifestations.[4] It is a common zoonosis in 
many parts of the world and is not uncommon in Iran. 
Neurobrucellosis accounted for 8% of all cases of brucellosis 
and is comparable to the reported frequency 5–10% in 
the earlier studies.[5,6] Headache, fever, sweating, weight 
loss, and back pain are the predominant symptoms in 
neurobrucellosis.[1,7] Meningitis and meningoencephalitis 
are the most common forms of neurobrucellosis.[8] 
Other neurological complications including myelitis, 
radiculoneuritis, brain abscess, epidural abscess, 
meningovascular syndromes, subarachnoid hemorrhage 
and psychiatric manifestations.[9] In our study meningitis 
and meningoencephalitis were the most common 
presentations. In this study the main reasons for delay 
in the diagnosis were less severe symptoms and lack 
of awareness of neurobrucellosis among the practicing 
physicians in this part of the world. 
Serum agglutination test is often used for screening and 
complement fixation or Coombs' test are confirmatory 
tests. ELISA for brucella is more sensitive and specific 
than other serological tests and it may replace other 
serological tests. ELISA may detect antibodies against 
brucella in the serum and CSF.[10-12] A patient with 
neurobrucellosis may have negative serological markers 
of brucellosis in the CSF and serum.[13] Lymphocytic 
pleocytosis and elevated proteins in CSF were the 
common abnormalities in our series. The diagnosis of 
neurobrucellosis can be considered despite negative 
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CSF culture and serology, based on clinical response 
and resolution of CSF abnormality with anti-brucella 
treatment.[13] 
Neurobrucellosis is a treatable disease with a favorable 
outcome. Doxycycline, rifampicin, ceftriaxone, 
trimethoprim sulfamethoxazole, ciprofloxacin 
and streptomycin have been found effective in 
neurobrucellosis.[14-16] Duration of treatment can depend 
on patient’s condition. If rapid improvement occurs we 
may shorten the duration of antibiotic therapy to 12 weeks 
and continue their treatment by clinical assessment. In 
the study by Bodur et al,[14] all patients received antibiotic 
therapy with ceftriaxone, rifampicin and doxycycline 
initially, and after one month they were continued 
with rifampicin and doxycycline up to four months. 
Doxycycline (by mouth) plus rifampin (by mouth) with 
ceftriaxone (intravenously) were the most common 
antibiotics in the study by Demiraslan et al.[17] Most of 
our patients received antibiotic treatment for 24 weeks 
and an acceptable response was seen within 12 weeks in 
seven (36%) patients. Short course of antibiotic therapy 
may be an option in patients with meningoencephalitis 
with no focal deficits or with minimal deficits. Patients 
with longer duration of the disease or with significant 
neurological deficits may require antibiotic treatment 
for a longer duration. Neurobrucellosis has an excellent 
prognosis when treated early and appropriately. The 
neurologic sequelae may be minimal. The important 
prognostic factors are duration of the disease, virulence 
of the microorganism and timing of antibiotic therapy. 
Early diagnosis and early institution of treatment is 
associated with fewer sequelae. 
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